EUCTR2008-001736-12-ES进行中（未招募）不适用
Estudio aleatorizado, doble ciego para determinar el efecto de dos pautas posológicas de R1507 o placebo, ambos en combinación con erlotinib (Tarceva®), sobre la supervivencia libre de progresión en pacientes con cáncer de pulmón no microcítico avanzado que haya progresado de la enfermedad tras haber recibido primera o segunda línea de quimioterapia..A Randomized, double blind study to determine the effect of two dose schedules ofR1507 or placebo, both in combination with erlotinib (Tarceva®), on progression-freesurvival in patients with advanced non-small cell lung cancer with disease progression after first or second line chemotherapy
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male and female patients, age ?18 years
- •2. Able to comply with the protocol
- •3. Patients must be able to take oral medication
- •4. Histologically documented inoperable, locally advanced or metastatic (stage IIIB and stage IV) NSCLC. (NOTE: Sputum cytology alone is not acceptable). Tumors with
- •mixed histology should be categorized according to the predominant cell type
- •5. Prior Treatment: Failed at least one, but no more than two standard chemotherapy regimens
- •6. Patients who have received maintenance chemotherapy between initial course of therapy (first line) and study entry may enter on the study provided they have not been treated with an agent that targets EGFR or IGF-1R
- •7. Formalin fixed paraffin embedded tumor tissue samples from initial or subsequent diagnosis representative of the disease must be available for shipment to Roche prior to randomization
- •8. Measurable disease according to RECIST
- •9. ECOG performance status 0-2
- •10. Life expectancy > 12 weeks
- •11. Adequate hematological function : ANC ?1.5 x 10 exp9/L; platelets ?100 x 10 exp9/L, Hb ?9 g/dL
- •12. INR ?1.5 and PTT ?1.5 x ULN unless receiving anticoagulant therapy
- •13. Adequate liver function: Serum bilirubin ?1.5 x ULN; transaminases ?2.5 x ULN (in case of liver metastases <5 x ULN)
- •14. Adequate renal function: Serum creatinine ? 1.5 X ULN
- •15. Serum calcium ? 1.1 X ULN
- •16. HbA1c ? 7%
- •17. Negative pregnancy test within 7 days of starting study treatment in pre-menopausal women and women < 2 years after the onset of menopause
- •18. Signed informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients must have had a head CT/MRI to evaluate for CNS metastasis within 28 days prior to enrollment. Patients with active CNS lesions are excluded. Patients with
- •radiographically stable, asymptomatic previously irradiated lesions are eligible provided patients is ? 4 weeks beyond completing cranial irradiation and ? 3 weeks off corticosteroid therapy
- •2. Prior treatment with an investigational or commercial agent that acts via IGF-1R inhibition
- •3. Prior treatment with an agent that acts via EGFR targeting
- •4. Administration of any anti-cancer therapies other than those administered in this study during protocol treatment
- •5. Administration of high doses of systemic corticosteroids. High dose is considered as > 20 mg of dexamethasone a day (or equivalent) for > 7 consecutive days.
- •Dexamethasone may induce CYP3A4 activity. CYP3A4 inhibitors and inducers may influence the plasma level of erlotinib
- •6. Prior irradiation: 1) Radiotherapy given within the last 4 weeks prior to first dose of study treatment. 2) Palliative radiotherapy for bone lesions outside the thoracic region within 2 weeks prior to the first dose of study treatment
- •7. Prior Surgery: Surgery (including open biopsy) or significant traumatic injury within the last 2 weeks prior to first dose of study treatment or anticipation of the need for
- •major surgery during study treatment
- •8. Patients must have recovered from any toxic effects of previously administered therapies and must be randomly assigned to study treatment at least 21 days after
- •chemotherapy (14 days after treatment with vinca alkaloids or gemcitabine)
- •9. Lactating women
- •10. Fertile men or women of childbearing potential not using effective methods to prevent pregnancy
- •11. Other active cancer requiring treatment
- •12. Known hypersensitivity to any of the study drugs or their excipients
- •13. Any disease (including psychotic disorders, drug abuse, active infection, uncontrolled hypertension, clinically significant cardiovascular disease for example CVA (? 6 months before randomization), myocardial infarction (? 6 months before randomization), unstable angina, NYHA ? grade 2 CHF, arrhythmia requiring medication, hepatic, renal or metabolic disease (including uncontrolled diabetes
- •mellitus), metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contra-indicates the
- •use of an investigational drug or puts the patient at high risk for treatment-related complications
- •14. History of allogeneic bone marrow transplantation or organ transplantation
- •15. Any known significant ophthalmologic abnormalities of the surface of the eye (the use of contact lenses is not recommended)
- •16. No dysphagia or active gastrointestinal disease or disorder that alters gastrointestinal motility or absorption; no lack of integrity of the gastrointestinal tract (e.g. as significant surgical resection of the stomach or small bowel). Patients
- •unable to swallow intact tablets must be able to swallow tablets dissolved in water
- •17. Treatment with any other investigational agent, or participation in another clinical trial within 30 days prior to starting study treatment
研究者
相似试验
进行中（未招募）
不适用
Estudio aleatorizado y doble ciego para establecer el momento más apropiado de la administración de la profilaxis antibiótica en la artroplastia total de rodilla cuando se realiza bajo isquemiaRandomized and double-blind study to establish the most appropriate moment for the administration of antibiotic prophylaxis for total knee arthroplasty performed under ischemiaEUCTR2006-006699-40-ESHospital Clínic
进行中（未招募）
1 期
Estudio aleatorizado, doble ciego, en el que se comparan los efectos de un régimen de clopidogrel durante 3 meses en combinación con AAS durante el primer mes, frente a AAS en monoterapia, para el tratamiento agudo de pacientes con AIT o ictus menor.Randomized, double-blind trial comparing the effects of a 3-month clopidogrel regimen, combined with ASA during the first month, versus ASA alone for the acute treatment of patients with TIA or minor stroke - CASTIAEl tratamiento agudo de pacientes con AIT o ictus menor.The acute treatment of patients with TIA or minor strokeMedDRA version: 8.1Level: HLTClassification code 10008192EUCTR2005-005763-28-ESSanofi-Aventis Groupe2,400
进行中（未招募）
不适用
Estudio aleatorizado y en doble ciego, dirigido a evaluar la eficacia y la seguridad de etanercept 50 mg dos veces a la semana y etanercept 50 mg una vez a la semana en el tratamiento de la psoriasis de grado moderado a severoA Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe PsoriasisPsoriasis en placa de grado moderado a severoModerate to severe plaque psoriasisEUCTR2007-001724-12-ESWyeth Pharmaceuticals France250
进行中（未招募）
不适用
Estudio aleatorizado, a doble ciego, controlado con placebo para evaluar la seguridad, tolerabilidad y eficacia de AMG 827 en sujetos con enfermedad de Crohn de moderada a grave / A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Moderate to Severe Crohn's DiseaseCrohn's disease / Enfermedad de CrohnMedDRA version: 12.1Level: LLTClassification code 10011408Term: Crohns disease aggravatedEUCTR2010-019544-39-ESAmgen Inc216
进行中（未招募）
不适用
Estudio aleatorizado, a doble ciego, controlado con placebo, exploratorio, con ajuste de dosis, de 12 semanas de seguimiento para evaluar la actividad antiepiléptica de BGG492 administrado por vía oral tres veces al día (TID) como tratamiento adyuvante en pacientes con crisis convulsivas de comienzo parcial resistentes al tratamientoepilepsiaMedDRA version: 12.1Level: LLTClassification code 10015037Term: EpilepsyEUCTR2010-018766-23-ESovartis Farmacéutica S.A57